Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Glioblastoma 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stage III Lung Non-Small Cell Cancer AJCC v7 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Liver Cirrhosis 1Gliosarcoma 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 46Radiotherapy 36Bevacizumab 34Carmustine 13Erlotinib Hydrochloride 11Irinotecan 10sargramostim 7Thalidomide 7Chemotherapy, Adjuvant 7Carboplatin 7Radiation 6pembrolizumab 5Topotecan 5Magnetic Resonance Spectroscopy 5Filgrastim 5Drug Therapy 5Cyclophosphamide 5aldesleukin 4Tamoxifen 4Surgical Procedures, Operative 4Sorafenib 4O(6)-benzylguanine 4Gefitinib 4Etoposide 4Celecoxib 4cediranib 3Radiotherapy, Intensity-Modulated 3Radiotherapy, Conformal 3Peripheral Blood Stem Cell Transplantation 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gliosarcoma × fluoromisonidazole × Clear all
NCT00902577 2019-04-08

MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled 16 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡